World's Best Scientists 2026 revealed!
Bernard Escudier

Bernard Escudier

Award Badge
Medicine
France
2023

D-Index & Metrics

Medicine

D-Index
127
Citations
95426
World Ranking
2762
National Ranking
70

Bernard Escudier publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Bernard Escudier sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 967 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Bernard Escudier D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Bernard Escudier sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 127 D-Index — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in France Leader Award

Overview

Bernard Escudier is affiliated with the Institut Gustave Roussy in France and focuses primarily on medical research related to oncology and renal cell carcinoma treatment. Their work intersects several fields of study, most notably Medicine, Biochemistry, Genetics and Molecular Biology, with specific emphasis on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, and Molecular Biology.

Their research covers key topics such as renal cell carcinoma treatment, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, as well as the economic and financial impacts of cancer. They have also contributed to studies on renal and related cancers, pancreatic and hepatic oncology research, and bladder and urothelial cancer treatments.

The scientist has published extensively in frequent publication venues, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • European Urology
  • Journal for ImmunoTherapy of Cancer

Recent significant papers authored or coauthored by Bernard Escudier include:

  • "Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma" (2021), New England Journal of Medicine
  • "Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade" (2020), Cancer Cell
  • "Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage" (2020), Science
  • "Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients" (2020), European Urology
  • "Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial" (2020), Cancer

Bernard Escudier collaborates frequently with several coauthors, including Laurence Albigès, Robert J. Motzer, Camillo Porta, David F. McDermott, and Ronan Flippot.

Best Publications

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    Bernard Escudier;Anna Pluzanska;Piotr Koralewski;Alain Ravaud

  • Renal cell carcinoma

    Brian I Rini;Steven C Campbell;Bernard Escudier

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    B. Escudier;C. Porta;M. Schmidinger;N. Rioux-Leclercq

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

    Bernard Escudier;Thierry Dorval;Nathalie Chaput;Fabrice André

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    Toni K. Choueiri;Thomas Powles;Mauricio Burotto;Bernard Escudier

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

    Sylvie Negrier;Bernard Escudier;Christine Lasset;Jean-Yves Douillard

  • CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

    Francois Ghiringhelli;Cédric Ménard;Magali Terme;Caroline Flament

  • Malignant effusions and immunogenic tumour-derived exosomes

    Fabrice Andre;Noel E C Schartz;Mojgan Movassagh;Caroline Flament

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

    Bernard Escudier;Joaquim Bellmunt;Sylvie Négrier;Emilio Bajetta

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

Frequent Co-Authors

Laurence Albiges
Laurence Albiges Institut Gustave Roussy
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Alain Ravaud
Alain Ravaud University of Bordeaux
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Thomas Powles
Thomas Powles Queen Mary University of London
Toni K. Choueiri
Toni K. Choueiri Harvard University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine opens doors to a wide range of related fields and advanced degrees. Many students consider healthcare leadership roles by enrolling in the cheapest mha programs online healthcare options. These programs can prepare future administrators to manage hospitals and healthcare organizations.

Nurses looking to take on clinical leadership or academic roles often turn to cheap online dnp programs to achieve a terminal degree in their field. If your interests lie more in the pharmaceutical sector, pursuing a 3-year online pharmd can help fast-track your career as a licensed pharmacist.

For those who want to focus on the intersection of technology and healthcare, a health information management degree online offers opportunities in data management, electronic health records, and medical informatics.

Exploring these affordable online degrees allows students and professionals to tailor their educational paths in medicine and healthcare, helping them reach specialized career goals beyond the traditional MD.

Best Scientists Citing Bernard Escudier

Trending Scientists